A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer

Tian Zhang, Michael R. Harrison, Peter H. O'Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, John M. Burke, Mark T. Fleming, Matthew I. Milowsky, Amir Mortazavi, Neal Shore, Guru P. Sonpavde, Emmett V. Schmidt, Bojena Bitman, Veerendra Munugalavadla, Raquel Izumi, Priti Patel, Janet Staats, Cliburn ChanKent J. Weinhold, Daniel J. George

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Sort by
Weight
Alphabetically

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer

Fingerprint

Medicine & Life Sciences